| Grant ID | DP250135 |
| Awarded On | November 20, 2024 |
| Title | Personalized Immunotherapy for Recurrent, Resectable Head and Neck Cancer |
| Program | Product Development Research |
| Award Mechanism | Texas Therapeutics Company Awards for Product Development Research |
| Institution/Organization | Metaclipse Therapeutics Corporation |
| Principal Investigator/Program Director | Christopher Pack |
| Cancer Sites | Head and Neck |
| Contracted Amount |
$6,080,245* *Pending contract negotiation |
| Lay Summary |
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer where new treatment options are urgently needed as current treatments are mostly ineffective in preventing metastasis and recurrence. Metaclipse Therapeutics, a clinical stage biotech, has developed a novel personalized therapeutic cancer vaccine (Membrex) for HNSCC, made of membrane vesicles from the patient's own tumor incorporated with immunostimulatory proteins to induce an immune response to kill tumor cells, thus preventing recurrence, metastasis and improve survival. Membrex vaccine is easily prepared and ready to be injected into the patient's skin within 18 days. CPRIT funds will enable a phase 1a/b clinical trial... |